Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide

What Was Tested

Researchers studied Octreotide in this randomized controlled trial publication.

The researchers aimed to determine the expression of SSTRs 1, 2a, 3, and 5 in somatotroph adenomas, to correlate expression with clinical characteristics and the response to octreotide, and to ascertain whether preoperative octreotide treatment affected SSTR expression.

Who Took Part

The study group was 78 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The study included 78 adenomas from patients operated on consecutively during 2000 to 2010.

After exclusion of 13 patients, immunohistochemical analysis with rabbit monoclonal antibodies against SSTRs 1, 2a, 3, and 5 (clones UMB-7, -1, -5, and -4) was performed on 65 adenomas.

How the Study Was Run

The researchers set it up as a randomized study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

Twenty-eight patients received preoperative octreotide, and 37 patients were operated on without pretreatment.

Twenty-six patients were randomized to direct surgery (n = 13) or to octreotide pretreatment (n = 13).

What Was Measured

Topics PubMed links to this paper include Acromegaly, Adenoma, Antibodies, Monoclonal, Antineoplastic Agents, Hormonal, Combined Modality Therapy, Growth Hormone-Secreting Pituitary Adenoma and Octreotide.

What This Means in Plain Language

The paper is a randomized study of Octreotide in 78 patients.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2013 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Octreotide compound page, all human trials.